Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma

Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma

Gd+-EOB-DTPA, a liver-specific contrast agent for magnetic resonance imaging (MRI), has intracellular and extracellular functions. The contrast agent can be absorbed into normal liver cells and excreted into the bile, with an absorption rate of about 50% and an excretion rate of about 50%. The autho...

Full description

Bibliographic Details
Main Authors: DING Ying, ZENG Mengsu
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2013-10-01
Series:Linchuang Gandanbing Zazhi
Online Access:http://www.lcgdbzz.org/qk_content.asp?id=5483
id doaj-e64ee670a3fe4ef99bf0d2ce842dc5e7
record_format Article
spelling doaj-e64ee670a3fe4ef99bf0d2ce842dc5e72020-11-24T23:00:22ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562013-10-01291073673910.3969/j.issn.1001-5256.2013.10.004Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinomaDING Ying0ZENG Mengsu1Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaGd+-EOB-DTPA, a liver-specific contrast agent for magnetic resonance imaging (MRI), has intracellular and extracellular functions. The contrast agent can be absorbed into normal liver cells and excreted into the bile, with an absorption rate of about 50% and an excretion rate of about 50%. The author reviews and summarizes the cases who underwent Gd+-EOB-DTPA-enhanced MRI in the Department of Radiology, Zhongshan Hospital in recent two years and focuses on the use of this contrast agent in following aspects: detection of early or small hepatocellular carcinoma (HCC), potential value for HCC grading, and differentiation between benign and malignant cirrhotic nodules in the multi-step progression of HCC. This review shows the effectiveness and unique advantage of Gd+-EOB-DTPA in the diagnosis of HCC, providing more comprehensive information for HCC patients.http://www.lcgdbzz.org/qk_content.asp?id=5483
collection DOAJ
language zho
format Article
sources DOAJ
author DING Ying
ZENG Mengsu
spellingShingle DING Ying
ZENG Mengsu
Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
Linchuang Gandanbing Zazhi
author_facet DING Ying
ZENG Mengsu
author_sort DING Ying
title Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
title_short Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
title_full Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
title_fullStr Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
title_full_unstemmed Clinical application of liver-specific contrast agent Gd+-EOB-DTPA in progression assessment and early diagnosis of hepatocellular carcinoma
title_sort clinical application of liver-specific contrast agent gd+-eob-dtpa in progression assessment and early diagnosis of hepatocellular carcinoma
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2013-10-01
description Gd+-EOB-DTPA, a liver-specific contrast agent for magnetic resonance imaging (MRI), has intracellular and extracellular functions. The contrast agent can be absorbed into normal liver cells and excreted into the bile, with an absorption rate of about 50% and an excretion rate of about 50%. The author reviews and summarizes the cases who underwent Gd+-EOB-DTPA-enhanced MRI in the Department of Radiology, Zhongshan Hospital in recent two years and focuses on the use of this contrast agent in following aspects: detection of early or small hepatocellular carcinoma (HCC), potential value for HCC grading, and differentiation between benign and malignant cirrhotic nodules in the multi-step progression of HCC. This review shows the effectiveness and unique advantage of Gd+-EOB-DTPA in the diagnosis of HCC, providing more comprehensive information for HCC patients.
url http://www.lcgdbzz.org/qk_content.asp?id=5483
work_keys_str_mv AT dingying clinicalapplicationofliverspecificcontrastagentgdeobdtpainprogressionassessmentandearlydiagnosisofhepatocellularcarcinoma
AT zengmengsu clinicalapplicationofliverspecificcontrastagentgdeobdtpainprogressionassessmentandearlydiagnosisofhepatocellularcarcinoma
_version_ 1725642439324073984

Similar Items